Andrew Lo

Professor of Finance, Andrew Lo, discusses the challenges of funding drug development and proposes a Netflix-inspired subscription model to address the crisis. Topics include innovative financing for biomedical innovation, the inspiring story of a life-saving drug, the value of death in biotech funding, challenges in paying for expensive medicines, breaking constraints in the payment system, and the potential of a subscription model for advanced therapies.

Dr. Andrew Lo, an MIT economist and biomedicine advocate, joins the conversation to unveil the intricate ties between finance and drug development. He shares his personal journey that shifted his focus towards healthcare finance and the establishment of QLS Advisors, applying data-driven methods to improve biotech success. The discussion highlights crucial factors predicting clinical trial outcomes and delves into revolutionary therapies like gene editing. Lo also addresses essential funding strategies needed to support high-risk treatments, aiming to transform patient care.

Andrew Lo, an MIT economist with a focus on healthcare economics, joins Jorge Conde to unravel the intricate world of pricey gene and cell therapies. They discuss the concept of treating payments for these innovations like a 'mortgage for a cure,' examining who pays and the potential system overload. The conversation explores the paradoxes of drug discovery, the promise of combination therapies, and how healthcare markets might operate like biological systems, revealing a dynamic interplay between economics and medicine.